ArticleHuman vaccines & immunotherapeutics2024
Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States.
Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Bivalent RSV Prefusion F Protein-Based Vaccine Effectiveness in Individuals With and Without Diabetes: A Prespecified Analysis of the DAN-RSV Trial.Diabetes care · 2026Article
- Respiratory Syncytial Virus Immunization Strategies for Older Adults in Gulf Cooperation Council Countries: Expert Consensus and Recommendations.Infectious diseases and therapy · 2026Article
- Integrating vaccine hesitancy into the health belief model: additive effects on parental decision-making for child RSV vaccination.BMC public health · 2026Article
- Article
- Knowledge, attitudes, and practices related to adult vaccination among adults and healthcare professionals across Mexico.PloS one · 2026Observational
- Awareness of respiratory syncytial virus and other respiratory disease vaccines among healthcare professionals and their patients in Italy: Insights from a literature review and a web-based survey.Human vaccines & immunotherapeutics · 2025Review
- Status of advanced respiratory syncytial virus antiviral therapeutics 2025.Current opinion in virology · 2025Review
- RSV vaccination uptake among adults aged 60 years and older in the United States during the 2023-2025 vaccination seasons.Human vaccines & immunotherapeutics · 2025Article
- Exploring parental awareness and willingness to use monoclonal antibodies for respiratory syncytial virus prevention.Human vaccines & immunotherapeutics · 2025Article
- Clinical features and outcomes of viral respiratory infections in adults during the 2023-2024 winter season.Scientific reports · 2025Observational
- Feasibility and Acceptability of Respiratory Syncytial Virus Vaccination in Mothers for Infant Protection at Edward Francis Small Teaching Hospital, the Gambia.Journal of epidemiology and global health · 2025Article
- Clinical and Socioeconomic Burden of RSV Infections Among Older Adults in Primary Care: An International Prospective Cohort Study.Influenza and other respiratory viruses · 2025Observational
- RSV Testing Patterns and Characteristics Associated with RSV Testing Among Adults Aged 50 Years or Older in the United States.Infectious diseases and therapy · 2025Article
- General Population and Healthcare Professionals' Level of Knowledge of the Burden and Prevention of Respiratory Syncytial Virus in France.Influenza and other respiratory viruses · 2025Article
- Prevention of respiratory syncytial virus disease across the lifespan in Italy.Pneumonia (Nathan Qld.) · 2025Review
- Healthcare Professionals' Knowledge, Attitudes, and Practices Regarding Respiratory Syncytial Virus Disease and Vaccination in Adults Aged 60 Years and Older.Infectious diseases and therapy · 2025Article
- Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.American journal of hematology · 2025Article
- Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review.Vaccines · 2025Review
- Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine.Medicina (Kaunas, Lithuania) · 2025Article
- Respiratory Virus Vaccines: Pathways to Recommendations and Enhanced Coverage for At-Risk Populations.Infectious diseases and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is associated with considerable morbidity and mortality among older adults (aged ≥60 years) and adults with certain chronic conditions in the United States (US). Despite this burden, no previous studies have assessed the knowledge, attitudes, and perceptions (KAP) of RSV among these populations. This study evaluates RSV-related KAP among US adults at increased risk of severe RSV infection. A cross-sectional, web-based survey was administered from May to June 2022 to better understand respiratory infection- and RSV-related KAP among US adults who are at risk of severe RSV infection. The survey included ≥200 adults in each of 4 subgroups: adults aged 60-89 years, and adults aged 18-59 years with ≥1 chronic cardiovascular condition, chronic pulmonary condition, or diabetes mellitus. Survey responses were analyzed descriptively overall and by subgroup, with exploratory logistic regression modeling used to evaluate characteristics associated with RSV awareness and concern. Among the 827 survey respondents, only 43.3% had ever heard of RSV (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.